Bioavailability of CoQ10The importance of Ceapro's PGX CoQ10 bioavailability results has been overlooked by the markets (stock). CoQ10 has the potential to treat a multitude of diseases, but bioavailability is an issue that needs to be solved.
From this paper's abstract (
https://journals.sagepub.com/doi/pdf/10.1177/2156587211399438 Coenzyme Q10 (CoQ10) supplementation has been reported to be beneficial in treating a variety of health conditions and diseases, with
more than 200 clinical trials investigating its use as a drug or dietary supplement. Numerous reviews of the safety and clinical potential of CoQ10 have been published.
Successful treatment and efficacy is dependent on the bioavailability of CoQ10, which is well known to be poor because of its lipophilic nature and large molecular weight.
PGX is a delivery system: beyond the recent PGX results for CoQ10, the door is open for pharma companies to investigate bioavailability roadblocks faced by their own bioactives by using PGX. These are exciting times for the company yet to be reflected in the share price.